Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter P Toth

Showing results (71-80 of 425) with videos related to

Pageof 43
Sort By:
Current Atherosclerosis Reports|August 12, 2006
The CARDS trial: diabetic patients dealt a winning handAnnemarie Armani, Peter P Toth
Clinical Therapeutics|November 9, 2004
Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalonePeter P Toth, Jason Urtis
Methodist Debakey Cardiovascular Journal|May 4, 2019
Statins: Then and NowPeter P Toth, Maciej Banach
Current Atherosclerosis Reports|August 12, 2009
Thienopyridine therapy and risk for cardiovascular events in secondary preventionPeter P Toth, Annemarie Armani
Postgraduate Medicine|November 2, 2020
Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care systemPeter P Toth, Diane Gauthier
Current Atherosclerosis Reports|November 16, 2007
SPARCL: the glimmer of statins for stroke risk reductionAnnemarie Armani, Peter P Toth
Expert Review of Cardiovascular Therapy|May 24, 2006
Colesevelam hydrochloride in the management of dyslipidemiaAnnemarie Armani, Peter P Toth
European Heart Journal Open|August 21, 2024
It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular diseasePeter P Toth, Maciej Banach
Journal of Clinical Lipidology|December 3, 2010
High-density lipoproteins: marker of cardiovascular risk and therapeutic targetPeter P Toth, Michael H Davidson
Heart Failure Clinics|September 25, 2012
Glucolipotoxicity and the heartPeter P Toth, Vasudevan A Raghavan
Pageof 43

Showing results (71-80 of 425) with videos related to

Sort By:
Pageof 43
Current Atherosclerosis Reports|August 12, 2006
The CARDS trial: diabetic patients dealt a winning handAnnemarie Armani, Peter P Toth
Clinical Therapeutics|November 9, 2004
Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalonePeter P Toth, Jason Urtis
Methodist Debakey Cardiovascular Journal|May 4, 2019
Statins: Then and NowPeter P Toth, Maciej Banach
Current Atherosclerosis Reports|August 12, 2009
Thienopyridine therapy and risk for cardiovascular events in secondary preventionPeter P Toth, Annemarie Armani
Postgraduate Medicine|November 2, 2020
Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care systemPeter P Toth, Diane Gauthier
Current Atherosclerosis Reports|November 16, 2007
SPARCL: the glimmer of statins for stroke risk reductionAnnemarie Armani, Peter P Toth
Expert Review of Cardiovascular Therapy|May 24, 2006
Colesevelam hydrochloride in the management of dyslipidemiaAnnemarie Armani, Peter P Toth
European Heart Journal Open|August 21, 2024
It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular diseasePeter P Toth, Maciej Banach
Journal of Clinical Lipidology|December 3, 2010
High-density lipoproteins: marker of cardiovascular risk and therapeutic targetPeter P Toth, Michael H Davidson
Heart Failure Clinics|September 25, 2012
Glucolipotoxicity and the heartPeter P Toth, Vasudevan A Raghavan
Pageof 43